NCT05472857View on ClinicalTrials.gov

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Gastric CancerPancreatic CancerAdvanced Ovarian CarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
BIOLOGICAL

Claudin 18.2 CAR-T

treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion

Trial Locations (1)

200000

RECRUITING

Changhai Hospital, Shanghai

All Listed Sponsors
collaborator

Changhai Hospital

OTHER

lead

Suzhou Immunofoco Biotechnology Co., Ltd

INDUSTRY